Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- PRLD
- Price
- 0.71
- Stock movement up
- +0.07 (10.35%)
- Company name
- Prelude Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 29.88M
- Ent value
- 59.53M
- Price/Sales
- 4.65
- Price/Book
- 0.19
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -85.69%
- 3 year return
- -54.24%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
PRLD does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 4.65 |
| Price to Book | 0.19 |
| EV to Sales | 9.27 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 42.18M |
| EPS (TTM) | -1.73 |
| FCF per share (TTM) | -1.42 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 6.42M |
| Gross profit (TTM) | 5.21M |
| Operating income (TTM) | -143.26M |
| Net income (TTM) | -131.52M |
| EPS (TTM) | -1.73 |
| EPS (1y forward) | -1.50 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 81.18% |
| Operating margin (TTM) | -2230.11% |
| Profit margin (TTM) | -2047.28% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 11.13M |
| Net receivables | 0.00 |
| Total current assets | 156.39M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 197.22M |
| Accounts payable | 5.92M |
| Short/Current long term debt | 18.14M |
| Total current liabilities | 22.22M |
| Total liabilities | 40.79M |
| Shareholder's equity | 156.43M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -105.72M |
| Capital expenditures (TTM) | 1.84M |
| Free cash flow (TTM) | -107.56M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -84.07% |
| Return on Assets | -66.69% |
| Return on Invested Capital | -82.63% |
| Cash Return on Invested Capital | -67.58% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.66 |
| Daily high | 0.71 |
| Daily low | 0.64 |
| Daily Volume | 191K |
| All-time high | 91.68 |
| 1y analyst estimate | 5.00 |
| Beta | 1.55 |
| EPS (TTM) | -1.73 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 5 May 2025 |
Downside potential
Loading...
Downside potential data
| PRLD | S&P500 | |
| Current price drop from All-time high | -99.23% | -12.89% |
| Highest price drop | -99.33% | -56.47% |
| Date of highest drop | 8 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -82.00% | -11.07% |
| Avg time to new high | 50 days | 12 days |
| Max time to new high | 1048 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
29.88M
Marketcap category
Small-cap
Description
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Employees
128
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page